LIPOGEMS ANNOUNCES LAST PATIENT ENROLLED IN THE U.S. FDA IDE ARISE STUDY FOR THE TREATMENT OF KNEE OSTEOARTHRITIS

ATLANTA, April 10, 2024 /PRNewswire/ — Lipogems, a clinical stage- global medical technology company, announces it has completed enrollment in the ARISE I U.S. FDA IDE study, which aims to examine MicroFat versus corticosteriod injection for the treatment of Knee Osteoarthritis (OA)….